AdoraPet Biosciences

Early Stage

Invest in Pets that don't cause allergies

Overview

Platform

Dealmaker Securities

Start Date

12/19/2022

Close Date

04/23/2023

Min. Goal

$50,000

Max. Goal

$5,000,000

Min. Investment

$1,000

Security Type

Equity - Common

Series

Pre-Seed

Funding Type

RegCF

Price Per Share

$5.00

Pre-Money Valuation

$35,000,000

Location

San Mateo, California

Industry

Pet Health, Food, and Services

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Low

Capital Intensity

High

Business Type

Growth

AdoraPet Biosciences, with a valuation of $20 million, is raising funds on DealMaker Securities. The company’s goal is to allow pets and owners to spend more time together by using state-of-the-art gene technology to eliminate the genes that cause allergies in owners and diseases in our pets. CRISPR is a Nobel Prize-winning technology scientists can use to remove problem-causing genes. AdoraPet plans to use CRISPR technology to modify these genes in embryos, creating allergy-free, long-living pets for everyone. Dr. Richard Chin, Dr. Stephen Sundlof and Dr. George Church founded AdoraPet in 2022. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5,000,000.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$0

$0

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$560

$0

Accounts Receivable

$0

$0

Total Assets

$560

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 12/19/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
AdoraPet Biosciences on DealMaker 2022
$
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $35,000,000

Follow company

Follow AdoraPet Biosciences on DealMaker 2022
View on Dealmaker Securities